Global Eosinophil Driven Diseases Market, By Type (Eosinophilic Esophagitis, Eosinophilic Granulomatosis with Polyangiitis, Hyper-eosinophilic Syndrome, Nasal Polyposis, Others), Treatment (Corticosteroids, Monoclonal Antibodies, Anti-cytokine Drugs, Cytotoxic Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Eosinophil Driven Diseases Market Analysis and Size
The global eosinophil driven diseases market is expected to witness significant growth during the forecast period. Rising prevalence of rare disorders worldwide and emerging markets are the factors responsible for the growth of this market. Growing cases of white blood cell related autoimmune disorders drives the eosinophil-driven diseases market. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the growth of eosinophil driven diseases market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global eosinophil driven diseases market in the forecast period 2022-2029. The expected CAGR of global eosinophil driven diseases market is tend to be around 7.0% in the mentioned forecast period. The market was valued at USD 150 million in 2021, and it would grow upto USD 257.73 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Eosinophils are the variety of white infection, allergy blood cells and one of the major immune system components helps in combating various and inflammatory diseases. Eosinophils develops and mature in the bone marrow and represent upto 6% of bone marrow. If the threshold of 1500 cells/μl crosses called as eosinophil-driven diseases, which causes severe inflammatory diseases and organ damage.
Eosinophil Driven Diseases Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Eosinophilic Esophagitis, Eosinophilic Granulomatosis with Polyangiitis, Hyper-eosinophilic Syndrome, Nasal Polyposis, Others), Treatment (Corticosteroids, Monoclonal Antibodies, Anti-cytokine Drugs, Cytotoxic Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Takeda Pharmaceutical Company Limited (Japan), Ellodi Pharmaceuticals (U.S.), Bristol-Myers Squibb Company (U.S.), AstraZeneca (U.K.), GSK plc (U.S.), Regeneron Pharmaceuticals Inc. (U.S.), Allakos Inc (U.S.), Arena Pharmaceuticals Ltd (U.S.), Revolo Biotherapeutics (U.S.), DBV Technologies (France), Cipla Inc (India), Sun Pharmaceutical Industries Ltd (India), Sanofi (France)
|
|
Market Opportunities
|
|
Global Eosinophil Driven Diseases Market Dynamics
Drivers
- Increasing Awareness about the disease
The rising awareness about the eosinophilic driven diseases is likely to drive the growth of market. For instance, The American Partnership for Eosinophilic Disorders (APFED) in collaboration with major pharmaceutical companies such as AstraZeneca plc, Sanofi S.A., Bristol Myers Squibb, Arena Pharmaceuticals, Inc. and others which provide support to the American Partnership for Eosinophilic Disorders (APFED) in order to organize National Eosinophil Awareness Week (NEAW). This boosts the market growth.
Opportunities
- Increased Clinical Research and Activities
Several drug candidates are developed and researched well for treating eosinophil driven diseases such as eosinophilic esophagitis, which have shown promising results in clinical trials. Consequently, regulatory authorities such as the U.S. FDA are being provided with designations to these drug candidates. For instance, Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, announced in February 2021, that the company has received Fast Track designation from the U.S. FDA for the treatment of Eosinophilic Esophagitis (EoE). This is a rare, chronic allergic inflammatory disease which is characterized by eosinophilic infiltration of the esophagus. This is another factor expected to drive growth of the leukotriene inhibitors market.
- Increasing Demand for Retail Pharmacies
Rise in the number of drugs for eosinophil driven diseases being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Impending Drug Approvals
There are many drugs or injections that await for the approval of the drugs. Receiving approval for the drug from regulatory authorities is a very tedious and challenging task as regulatory authorities such as the U.S. FDA execute substantial and burdensome requirements upon companies involved in the clinical development, marketing, manufacturing, and distribution of drugs
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global eosinophil driven diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global eosinophil driven diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Eosinophil Driven Diseases Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials. A number of research activities have been performed to understand the relation between the COVID-19 and eosinophil driven diseases such as eosinophilic esophagitis. Additionally, research has been ongoing in which researchers are trying to understand the correlation of mortality in patients due to the COVID-19 and eosinophilic esophagitis.
In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will leave a significant impact on the global eosinophil driven diseases market.
Recent Developments
- In January 2020, three clinical trials announced for Fasenra in eosinophil-driven skin diseases. In this, 2 Phase II trials assess the medicine's potential in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU); and 1 Phase III trial in bullous pemphigoid. If approved, Fasenra would be first-line, first-choice treatment for patients with eosinophil-driven diseases.
Global Eosinophil Driven Diseases Market Scope
The global eosinophil driven diseases market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Eosinophilic Esophagitis
- Eosinophilic Granulomatosis with Polyangiitis
- Hyper-eosinophilic Syndrome
- Nasal Polyposis
- Others
Treatment
- Corticosteroids
- Monoclonal Antibodies
- Anti-cytokine Drugs
- Cytotoxic Drugs
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Eosinophil Driven Diseases Market Regional Analysis/Insights
The global eosinophil driven diseases market is analysed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global eosinophil driven diseases market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global eosinophil driven diseases market throughout the forecasted period due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.
North America dominates the market due to the global leaders in research and development activities and vulnerable asthma population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Eosinophil Driven Diseases Market Share Analysis
The global eosinophil driven diseases market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global eosinophil driven diseases market.
Key players operating in the global eosinophil driven diseases market include:
- Takeda Pharmaceutical Company Limited (Japan)
- Ellodi Pharmaceuticals (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- AstraZeneca (U.K.)
- GSK plc(U.S.)
- Regeneron Pharmaceuticals Inc. (U.S.)
- Allakos Inc (U.S.)
- Arena Pharmaceuticals Ltd (U.S.)
- Revolo Biotherapeutics (U.S.)
- DBV Technologies (France)
- Cipla Inc (India)
- Sun Pharmaceutical Industries Ltd (India)
- Sanofi (France)
SKU-